Regeneron Pharmaceuticals, Inc. (REGN) Up 11.5% — Time to Take the Plunge?
Regeneron Pharmaceuticals, Inc. (REGN) is surging this Friday, last changing hands at $912.93 on the NASDAQ — a $94.16 gain from the prior close of $818.77. The move sends the stock into new territory. REGN now trades roughly 6.2% above its previous 52-week high of $859.34, a level set on September 3, 2026. Clearing that ceiling by this much in a single session shows how sharply the market has re-rated the name on today's news.
Volume is running at approximately 1.41 million shares, nearly double the 90-day average of roughly 737,420. That level of participation confirms that buyers arrived in force behind the breakout.
Why Regeneron Pharmaceuticals, Inc. Price is Moving Higher
The driver is a decisive Q3 earnings beat. Regeneron reported adjusted EPS of $20.07 against $16.42 estimate, a beat of more than 22%. Revenue reached $5.116 billion versus the $4.56 billion consensus. Year over year, revenue climbed 36% and adjusted EPS jumped 70%, while net income rose 33% to $1.949 billion. Results that far above expectations reset the earnings base for a company of Regeneron's size, and the market repriced the stock accordingly.
The Sanofi (SNY) partnership powered the quarter. Sanofi collaboration revenue jumped 68% to $2.724 billion, as Regeneron's share of antibody profits rose to $2.575 billion from $1.456 billion. Dupixent sales grew 35% to $6.54 billion. The development balance owed to Sanofi was fully repaid by the end of Q2, so it no longer reduced collaboration revenue in Q3. That makes the profit uplift structural rather than one-time. Management also raised its 2026 adjusted product gross margin outlook to about 86% from 84%–85% and cut its adjusted SG&A forecast by $100 million at both ends of the range, while increasing planned R&D spending. A newly expanded Sanofi antibody deal adds $1 billion upfront, to be recognized as Q4 revenue, plus up to $7 billion in potential milestones. That gives investors a visible boost to next quarter's numbers.
The report also offered encouraging signs on the Eylea transition. U.S. Eylea sales fell 41% to $400 million, but Eylea HD rose 62% to $699 million. The next-generation formulation is now more than offsetting the decline of the original product. Drug stocks broadly firmed on Friday. Gilead Sciences, Inc. (GILD) rose 4.05% and Merck & Co., Inc. (MRK) added 2.21%, while AstraZeneca (AZN) gained more than 6%. REGN's 11.50% advance far outpaced the group, which marks this as a company-specific earnings rally.
What is the Regeneron Pharmaceuticals, Inc. Rating - Should I Buy?
Weiss Ratings assigns REGN a C rating. Current recommendation is Hold. The rating balances a financially formidable business against a stock that has historically delivered an uneven ride for shareholders. Today's results strengthen the fundamental half of that equation considerably.
The operating profile is where Regeneron shines. Its Excellent rating on the Efficiency Index is supported by a 27.86% profit margin, a strong figure for a company that funds one of the industry's heaviest research programs. The newly raised 86% product gross margin target suggests that profitability has room to improve further. Regeneron is also rated Excellent on the Solvency Index. Its balance sheet can absorb rising R&D commitments and business-development spending without strain, and it now has a $1 billion upfront payment arriving in Q4. The Good rating on the Growth Index reflects 16.73% revenue growth. That is solid expansion, held back from the top tier by the steady erosion of legacy Eylea sales. Q3's 36% revenue surge shows that growth is accelerating as Dupixent profits and Eylea HD carry more of the load. With EPS of $40.46 and a forward P/E of 20.24, the valuation remains reasonable for a business compounding at this pace.
Where the picture becomes more nuanced is in the market-facing measures. The Fair rating on the Total Return Index reflects a stock that has spent long stretches range-bound while investors debated the Eylea cliff, even if today's breakout to new highs begins to reward patient holders. The Weak Volatility Index rating comes into focus on a day like this one. An 11.50% single-session swing on an earnings surprise is welcome to the upside, but it shows how sharply the shares react to quarterly results in either direction. The Weak rating on the Dividend Index reflects a 0.45% yield. Regeneron is primarily a growth and buyback story rather than an income holding. These three dimensions keep the overall rating at C rather than in Buy territory.
Within the Health Care sector, Regeneron sits alongside Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Pfizer Inc. (PFE, C). It ranks ahead of Chugai Pharmaceutical Co., Ltd. (CHGCF, C-). Few of those names posted a quarter as strong as the one Regeneron delivered today.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a Health Care company ounded in 1988 and headquartered in Tarrytown, New York. Regeneron discovers, develops, manufactures, and commercializes medicines for serious diseases across ophthalmology, immunology and inflammation, oncology, cardiovascular and metabolic disorders, and rare diseases. Its flagship ophthalmology franchise is built on Eylea and the higher-dose Eylea HD, both used to treat wet age-related macular degeneration, diabetic macular edema, and related retinal conditions.
Regeneron's largest profit engine is Dupixent, developed and commercialized with Sanofi. It is used for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and COPD, among other type 2 inflammatory diseases. The Sanofi collaboration also covers Kevzara for rheumatoid arthritis. Regeneron's own portfolio includes Libtayo, a PD-1 inhibitor for several cancers including cutaneous squamous cell carcinoma and non-small cell lung cancer. It also markets Praluent for lowering LDL cholesterol and Evkeeza for homozygous familial hypercholesterolemia.
The company's competitive edge rests on its proprietary discovery platforms. VelocImmune mice generate fully human antibodies, which has allowed Regeneron to build a deep pipeline of antibody and bispecific candidates at notable speed. The Regeneron Genetics Center operates one of the world's largest human sequencing efforts, linking genetic data to drug targets. Together with in-house manufacturing scale and long-standing partnerships, these platforms support a research engine that consistently feeds new programs into late-stage development.
Investor Outlook
Regeneron Pharmaceuticals, Inc. (REGN) carries a Weiss Rating of C (Hold), and today's breakout above its prior 52-week high of $859.34 gives investors a fundamentally upgraded story to evaluate. Investors should watch the $1 billion upfront Sanofi payment flowing into Q4 revenue, continued Eylea HD momentum against legacy Eylea declines, and whether Dupixent keeps delivering growth in the 35% range. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--